Examples are studies exploring BV R-mini-CHP regimen (brentuximab vedotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen as the first line for elderly DLBCL patients [84], BV-AVD as the first line for PTCL patients other than systemic ALCL with low CD30 expression [85], BV-ICE (brentuximab vedotin, ifosfamide, carboplatin, etoposide) for R/R HL patients [86], brentuximab vedotin plus the HDAC inhibitor romidepsin for systemic CTCL patients requiring therapy [87]. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.